EP1572916A4 - NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE NAME 98P4B6, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER - Google Patents

NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE NAME 98P4B6, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER

Info

Publication number
EP1572916A4
EP1572916A4 EP03719599A EP03719599A EP1572916A4 EP 1572916 A4 EP1572916 A4 EP 1572916A4 EP 03719599 A EP03719599 A EP 03719599A EP 03719599 A EP03719599 A EP 03719599A EP 1572916 A4 EP1572916 A4 EP 1572916A4
Authority
EP
European Patent Office
Prior art keywords
cancer
useful
detection
treatment
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03719599A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1572916A2 (en
Inventor
Pia M Challita-Eid
Arthur B Raitano
Mary Faris
Wangmao Ge
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/165,044 external-priority patent/US20030149531A1/en
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of EP1572916A2 publication Critical patent/EP1572916A2/en
Publication of EP1572916A4 publication Critical patent/EP1572916A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
EP03719599A 2002-04-05 2003-04-04 NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE NAME 98P4B6, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER Withdrawn EP1572916A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US37038702P 2002-04-05 2002-04-05
US370387P 2002-04-05
US165044 2002-06-06
US10/165,044 US20030149531A1 (en) 2000-12-06 2002-06-06 Serpentine transmembrane antigens expressed in human cancers and uses thereof
US43548002P 2002-12-20 2002-12-20
US435480P 2002-12-20
PCT/US2003/010462 WO2003087306A2 (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer

Publications (2)

Publication Number Publication Date
EP1572916A2 EP1572916A2 (en) 2005-09-14
EP1572916A4 true EP1572916A4 (en) 2007-05-30

Family

ID=29255235

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03719599A Withdrawn EP1572916A4 (en) 2002-04-05 2003-04-04 NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE NAME 98P4B6, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER

Country Status (8)

Country Link
EP (1) EP1572916A4 (pt)
JP (1) JP2005534287A (pt)
AU (2) AU2003223469A1 (pt)
BR (1) BR0308953A (pt)
CA (1) CA2481503A1 (pt)
MX (1) MXPA04009728A (pt)
NZ (1) NZ535762A (pt)
WO (1) WO2003087306A2 (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5020636B2 (ja) 2003-11-06 2012-09-05 シアトル ジェネティックス， インコーポレイテッド リガンドに結合体化可能なモノメチルバリン化合物
WO2005079490A2 (en) * 2004-02-13 2005-09-01 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
US7642072B2 (en) * 2004-07-26 2010-01-05 Enzon Pharmaceuticals, Inc. Optimized interferon-beta gene
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JP2012531212A (ja) 2009-07-03 2012-12-10 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法
IN2012DN03025A (pt) 2009-09-09 2015-07-31 Ct Se Llc
WO2011075786A1 (en) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
AU2012245073B2 (en) 2011-04-21 2016-02-11 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
CN103987407B (zh) 2011-10-14 2016-08-24 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其偶联物
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
JP6392764B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
CA2941485C (en) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines and conjugates thereof
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
SI2906298T1 (sl) 2012-10-12 2018-12-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo
WO2014057113A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine - anti-psma antibody conjugates
CN105189507A (zh) 2012-12-21 2015-12-23 斯皮罗根有限公司 吡咯并苯并二氮杂卓及其结合物
JP6527466B2 (ja) 2012-12-21 2019-06-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体
EP2968585B1 (en) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2016001862A (es) 2013-08-12 2016-08-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3082875B1 (en) 2013-12-16 2020-11-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
EP3388449A3 (en) 2014-09-12 2018-10-24 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CR20170099A (es) 2014-09-17 2017-07-19 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
MX2017007169A (es) 2014-12-03 2018-05-02 Genentech Inc Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
MX2019003325A (es) * 2016-09-23 2019-08-05 Regeneron Pharma Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos.
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
LT3544636T (lt) 2017-02-08 2021-06-25 Adc Therapeutics Sa Pirolobenzodiazepino-antikūno konjugatai
HUE059828T2 (hu) 2017-04-18 2023-01-28 Medimmune Ltd Pirrolobenzodiazepin konjugátumok
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
BR112019026564A2 (pt) 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
SG11202001907QA (en) 2017-09-20 2020-04-29 Ph Pharma Co Ltd Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US20210315870A1 (en) * 2020-04-10 2021-10-14 Postsurgical Therapeutics, Inc. Combinatorial targeted therapy methods
BR112023000489A2 (pt) 2020-07-13 2023-03-28 Regeneron Pharma Análogos de camptotecina conjugados a um resíduo de glutamina em uma proteína, e seu uso
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040276A2 (en) * 1999-12-06 2001-06-07 Agensys, Inc Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof
WO2001072962A2 (en) * 2000-03-24 2001-10-04 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040276A2 (en) * 1999-12-06 2001-06-07 Agensys, Inc Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof
WO2001072962A2 (en) * 2000-03-24 2001-10-04 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods

Also Published As

Publication number Publication date
EP1572916A2 (en) 2005-09-14
AU2003223469A1 (en) 2003-10-27
CA2481503A1 (en) 2003-10-23
WO2003087306A8 (en) 2006-10-05
JP2005534287A (ja) 2005-11-17
AU2009230789A1 (en) 2009-11-19
BR0308953A (pt) 2006-03-14
MXPA04009728A (es) 2005-06-08
NZ535762A (en) 2009-04-30
WO2003087306A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
EP1572916A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE NAME 98P4B6, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER
AU2003243151A8 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
HK1152714A1 (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer steap-1
EP1537140A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN 161P2F10B USEFUL IN THE TREATMENT AND DETECTION OF CANCER
AU2002318112B2 (en) Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1517606A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN CURED 193P1E1B USEFUL IN THE TREATMENT AND DETECTION OF CANCER
EP1622571A4 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS CURED 109P1D4 USEFUL IN THE TREATMENT AND DETECTION OF CANCER
PT1537140E (pt) Ácido nucleico e proteína correspondente designada 161p2f10b úteis no tratamento e detecção de cancro
EP1372719A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE NAME 125P5C8 FOR THE TREATMENT AND DETECTION OF CANCER
EP1590437A4 (en) NUCLEIC ACIDS SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER AND CORRESPONDING PROTEINS NAMED 254P1D6B
EP1409710A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN, DESIGNATED BY 161P5C5, FOR THE TREATMENT AND DETECTION OF CANCER
AU2002246708A1 (en) Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
AU2001285018A1 (en) Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
EP1565200A4 (en) NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER
EP1578980A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN 213P1F11 FOR USE IN THE TREATMENT AND DETECTION OF CANCER
AU2003268355A8 (en) Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells
EP1539805A4 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS SAID 101P3A11 OR PHOR-1 FOR THE TREATMENT AND DETECTION OF CANCERS
EP1545556A4 (en) NUCLEIC ACID AND CORROSIVE PROTEIN 98P4B6 FOR THE TREATMENT AND DETECTION OF CANCER
EP1399174A4 (en) NUCLEIC ACID AND RELATED PROTEIN, TREATABLE AND DETECTABLE FOR CANCER, NAME 121P1F1
EP1499350A4 (en) NUCLEIC ACID AND ASSOCIATED PROTEIN HAVING NAME 205P1B5 FOR USE IN THE TREATMENT AND DETECTION OF CANCER
IL164390A0 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
ZA200501838B (en) Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
AU2001286541A1 (en) Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer
AU2002305170A1 (en) Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
AU2012244341A1 (en) Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041025

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080113

Country of ref document: HK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20070109BHEP

Ipc: G01N 33/574 20060101ALI20070109BHEP

Ipc: C12Q 1/68 20060101ALI20070109BHEP

Ipc: C07K 16/30 20060101ALI20070109BHEP

Ipc: C07K 14/705 20060101AFI20070109BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070427

17Q First examination report despatched

Effective date: 20080730

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090210

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1080113

Country of ref document: HK